• Save 15%

Daflon 60 tablets 50mg 023356049

  • 023356049
Daflon is a drug based on the active ingredient diosmin + hesperidin - belonging to the category of Capillaroprotectors and specifically Bioflavonoids. Daflon can be prescribed with SOP Recipe - non-prescription medicine. Symptoms attributable to venous insufficiency; states of capillary fragility. Symptomatic treatment of acute haemorrhoidal crisis.
info_outline View product sheet
Final Price €22.95
Regular Price €27.00
Save 15%
check_circle Available (12 Items)

redeem loyalty points

By buying this product you can collect up to 22 loyalty points that can be converted into a voucher. More info

  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Other products Others products at unbeatable price


Discover all products


Therapeutic indications

Symptoms attributable to venous insufficiency; states of capillary fragility. Symptomatic treatment of acute hemorrhoidal crisis.

Dosage and method of use

DosageVenous insufficiency (also of the haemorrhoidal plexus) and capillary fragilityThe recommended dose is 2 tablets to be taken in two doses per day. Do not exceed the maximum daily dose.Acute hemorrhoidal crisisThe recommended dose is 3 tablets twice a day during the first 4 days of treatment; in the following 3 days the daily dose is 4 tablets in two doses. Do not exceed the maximum daily dose. Method of administration Take the tablets with the two main meals. Duration of treatment The treatment must not be continued beyond 7 days. In the absence of a therapeutic response, reassess the situation.


Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Side effects

The following adverse effects or reactions have been reported and ranked under the following frequency: very common (≥1 / 10); common (≥1 / 100, Nervous system disorders Rare: dizziness, headache, malaiseGastrointestinal disordersCommon: diarrhea, dyspepsia, nausea, vomiting Uncommon: colitis Not known: abdominal painSkin and subcutaneous tissue disordersRare: rash, pruritus, urticaria Not known: edema of the face, lips, eyelid; Quincke's edemaDisorders of the blood and lymphatic systemNot known: thrombocytopeniaReporting of suspected adverse reactionsReporting of suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

Important information about some of the ingredients Daflon contains less than 1 mmol (23 mg) sodium per tablet, i.e. essentially 'sodium-free'.

Pregnancy and breastfeeding

PregnancyData on the use of purified micronized flavonoic fraction in pregnant women do not exist or are limited in number. Animal studies do not indicate reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Daflon during pregnancy.Feeding timeIt is not known whether the active substance / metabolites are excreted in human milk. A risk to the newborns / infants cannot be excluded A decision must be made whether to discontinue breast-feeding or to discontinue / abstain from Daflon therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for women.FertilityReproductive toxicity studies showed no effects on fertility in either male or female rats (see section 5.3).

Expiry and retention

This medicinal product does not require any special storage conditions.

Interactions with other drugs

No interaction studies have been performed. To date, no clinically relevant drug interactions have been reported from post marketing experience on the product.


SymptomsThere is limited experience with Daflon overdose. The most frequently reported adverse events in overdose cases were gastrointestinal events (such as diarrhea, nausea, abdominal pain) and skin events (such as pruritus, rash).ManagementManagement of overdose should consist of treatment of clinical symptoms.

Active principles

Each film-coated tablet contains 500 mg of purified micronized flavonoic fraction consisting of 450 mg of diosmin and 50 mg of flavonoids expressed in hesperidin. For the full list of excipients, see section 6.1.


Sodium carboxymethyl starch, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulfate, yellow iron oxide E172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.

12 Items

Data sheet

500 mg 60 film-coated tablets
Product Type
ATC code
ATC description
Diosmin - associations
Therapeutic Group
Capillary protectors
Active principle
diosmin + hesperidin
Pharmaceutical form
coated tablets
Type of Administration
cpr / cps / pills / confetti in blister packs
60 tablet
Quantity of the Active Ingredient
450MG (diosmin) + 50MG (hesperidin)
Recipe required
SOP - non-prescription medicine